1 how to use irrelevant plasma and urine drug concentration in doping control in the fei. pl toutain...
TRANSCRIPT
![Page 1: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/1.jpg)
1
How to use irrelevant plasma and urine drug concentration in doping
control in the FEI.
PL ToutainUMR 181 Physiopathologie et Toxicologie Expérimentales; INRA, ENVT; 22nd July 2010
ECOLENATIONALEVETERINAIRET O U L O U S E
![Page 2: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/2.jpg)
2
Objectives of the presentation
• To explain the EHLSC risk analysis approach:– To determine Irrelevant Plasma (IPC) & Irrelevant Urine
Concentration (IUC)– To select an International Screening Limit (ISL)– To obtain a Detection Time (DT)– To transform a DT to a Withdrawal Time (WT)
• In order to see how FEI can used these information either directly or after its own risk analysis.
![Page 3: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/3.jpg)
3
The European Horse Scientific Liason Committee
The view expressed in this presentation are those of the author and do not commit the official policy of the EHLSC
![Page 4: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/4.jpg)
4
An anti-doping program is first characterized by a set of values
• Sound science does not exist as 'ready for use' in the policy development process; – Before to explore how FEI can use
International Screening Limits (ISL) as derived by EHSLC, FEI should formally express its set of values:
![Page 5: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/5.jpg)
5
What is a clean sport?
• Only a level playing field?
• Does this include protection of the horse?
–If yes, what is the priority: to protect the horse or to protect a business model?
![Page 6: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/6.jpg)
6
Science vs. values
• It should be admitted that science is not able to resolve FEI choices about what should be done in the case of competing interests.
• Science is universal, not ethics
• A risk for FEI is to raise a question that is mainly of ethical nature and attempt to solve it using scientific arguments
![Page 7: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/7.jpg)
7
An anti-doping program is first characterized by a set of values
• Prohibition of the presence of any substances which could give a horse an advantage or a disadvantage in a horse during a race (or training)
• BUT:• The goal of the EHSLC policy is not to indirectly impede
bona fide veterinary medications – and EHSLC have established a general policy that distinguishes
the control of any drug exposure for all illicit substances (doping control) and the control of a drug effect for therapeutic substances (medication control).
![Page 8: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/8.jpg)
8
Testing exposure and the end of a zero tolerance approach for medication control
Need for limitation on the sensitivity of testing for therapeutic agents
!
(ng/ml)
10
1.0
0.1
20 50 100 Time (days)
5 h
2 days
20 days
Detection time
![Page 9: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/9.jpg)
9
The current analytical techniques are very performing and laboratory equipments are not a
limiting factors to the efficiency of most drugs
![Page 10: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/10.jpg)
10
Testing exposure and the end of a zero tolerance approach for medication control
• Increasing sensitivity of analytical techniques is :– Desirable for potent illegitimate drugs– Unsuitable for therapeutic substances
• because trace concentrations of therapeutic substances totally irrelevant in terms of effects, may be detected a long time after their administration
![Page 11: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/11.jpg)
11
Doping control policy at time of racing
• The EHSLC' question– How to avoid to detect trace level of drugs
without any pharmacological meaning
• The question in operational terms– What should be the order of magnitude of
LOD (LOQ) of analytical techniques for the control of drug effect (not drug exposure )
![Page 12: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/12.jpg)
12
The “zero tolerance rule” is not suitable for medication control
• This opens the way to a new approach for legitimate medication based upon PK/PD principles to estimate the order of magnitude of the so-called irrelevant drug concentrations in plasma and urine and to limit the sensitivity of analytical techniques used for medication control.
![Page 13: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/13.jpg)
13
The decision making process on no significant effect levels
by EHSLC. A risk analysis integrated
approach
![Page 14: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/14.jpg)
14
What is risk analysis?
A systematic way of collecting, evaluating and recording information leading to recommendations for a position or action in response to an identified hazard (here medications or illicit substances)
![Page 15: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/15.jpg)
15
The 3 main steps of a Risk analysis
1. Risk assessment
2. Risk management
3. Risk communication
Science
Decision
Communication
Irrelevant Plasma concentrationIrrelevant Urine Concentration
International screening limits
Detection Times
![Page 16: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/16.jpg)
16
Why a risk analysis
• The reasons to follow a risk analysis are when harmonization is in order, regulatory decisions need to take into account competitive interests in an unbiased and transparent approach.
![Page 17: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/17.jpg)
17
FEI will benefit to apply Risk Analysis techniques in making
better decision
![Page 18: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/18.jpg)
18
An example: Phenylbutazone
![Page 19: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/19.jpg)
19
The 3 main steps of a Risk analysis
1. Risk assessment
2. Risk management
3. Risk communication
![Page 20: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/20.jpg)
20
The PK/PD approach to determine irrelevant plasma or
urine drug concentrations
Steps :
1: effective plasma concentration (EPC)
2: Irrelevant plasma concentration (IPC)
3: Irrelevant urine concentration (IUC)
![Page 21: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/21.jpg)
21
ED=
ED - is a hybrid parameter (PK and PD)
- is not a genuine PD drug parameter
Clearance x Effective plasma Concentration
Bioavailability
PD
PK
What is exactly an effective dose (ED) ?
![Page 22: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/22.jpg)
22
Computation of an Effective Plasma Concentration (EPC)
Clearance
DoseEffectiveEPC
_
![Page 23: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/23.jpg)
23
Step 1 : example of phenylbutazone
• Standard dose: 4.4 mg/kg/24 h• Plasma clearance: 41 mL/kg/h or about 1000 mL/kg/24 h
EPC = 4400 µg.kg-1.24h-1
1000 mL.kg-1.24h-1= 4.4 µg/mL
Note: from PK/PD, 1.5 to 4.3 µg/mL
Progressive list : up to 8µg/mL meaning a dose of about 8 mg/Kg/24h
![Page 24: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/24.jpg)
24
Freund adjuvant arthritis in horse
Carpitis
![Page 25: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/25.jpg)
25
12
14
8
4
00 4 8 12 16 20 24
Time(h)Str
ide
len
gth
(cm
)
1.25
1.0
1.5 2 4
DOSE mg/kg
PK/PD: Phenylbutazone
![Page 26: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/26.jpg)
26
8
0
16
0 4 8 12 16 20 24 h
Str
ide
len
gth
(c
m) 1
0.5
2
DOSE mg/kg
PK/PD: Flunixine
![Page 27: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/27.jpg)
27
Step 2: computation of irrelevant plasma concentrations
• An IPC can be deduced from EPC by applying a safety factor (SF) to EPC:
IPC = EPCSF
How to select SF?!
![Page 28: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/28.jpg)
28
Step 2: how to select safety factor
SF
Valuesconsiderations
Scientific considerations
• shape of the dose-effect relationship
• paucity of data• class of the drug• large interindividual variability• effect having different potency
Should reflect the degree of confidence we want the IPC is actually an IPC (Values)EHSLC: no effect (2%)
![Page 29: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/29.jpg)
29
Safety factor: default EHSLC value=500
• I proposed a default SF = 500
500 = 50 x 10
Transform an EPC into an IPC for a given horse
![Page 30: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/30.jpg)
30
Safety factor : 50
Emax100
2
EC50 = EPCEC50
50With a SF=50, effect is about 2% of the effect of interest
Eff
ect
(%)
![Page 31: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/31.jpg)
31
Safety factor: default EHSLC value=500
• I proposed a default SF = 500
500 = 50 x 10
Transform an EPC into an IPC for a given horse
Interindividual horse variability
PK variability PD variability
Level playing field require to take into account variability
![Page 32: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/32.jpg)
32
Step 2 : the case of Phenylbutazone
by rounding up: IPC= 10 ng/mL
mLngmLngEPC
IPC /8.8500/4400
500
![Page 33: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/33.jpg)
33
Step 3: determination of irrelevant urine concentration (IUC)
IUC = IPC x RSS
steady state urine to plasma concentration ratio
urine
Pseudo-equilibrium state
Plasma
10
1
con
cen
trat
ion
(time)
Plasma
Urine
Rss = 10
![Page 34: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/34.jpg)
34
Step 3 irrelevant urine concentration (IUC): the case of PBZ
• RSS = 1
• IUC = IPC x RSS
• IUC = 10 ng/mL x 1 = 10 ng/mL
![Page 35: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/35.jpg)
35
The 3 main steps of a Risk analysis
Risk assessment
Risk management
Risk communication
![Page 36: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/36.jpg)
36
Risk managementDetermination of the ISL
International Screening Limits:
An instruction (expressed as a concentration) to laboratories from racing authorities to control the detection of drugs commonly used in equine medication at a level that is considered NOT to be threat to welfare of the horse, alter its racing or compromise the integrity of racing
![Page 37: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/37.jpg)
37
From the IPC/IUC to the ISL
• ISLs are fixed by risk managers (FEI vs. EHSLC)– Risk management is not a scientific exercise but
should be scientifically sound– Possibility to consider at this step non scientific
considerations as harmonization– IPCs/IUCs are starting values
– selection of one of the values of the possible values of
the agreed ordinal scale
![Page 38: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/38.jpg)
38
Why an ordinal scale?
• Selection of an ISL is a non quantitative decision and cannot be assimilated to a statistically founded threshold (as for cortisol, testosterone…)
• Results of controls are qualitative (yes or no) and not quantitative
![Page 39: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/39.jpg)
39
From IUC to IPC: An hypothetical example
• It is a Anti-inflammatory drug• IUC=38 ng/mL• Possible values of the ordinal scale for a ISL
– 10, 50, 100, 250, 500 etc• The manager will likely choose either 10 or 50 ng/mL,
the 2 values that bracket the IUC• The final choice will take into account the difficulty or
not to harmonize, if the drug is of major concern or not etc.
• It is mainly at that level that FEI can differentiate its conclusions from those of EHSLC
![Page 40: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/40.jpg)
40
The 3 main steps of a Risk analysis
Risk assessment
Risk management
Risk communication
![Page 41: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/41.jpg)
41
Risk communication
Detection Times vs.
Withdrawal Times
![Page 42: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/42.jpg)
42
The question of Detection Time (DT)
• For medication control ISL is not "ready for use" information for veterinarians who must advise owners or trainers on appropriate withholding times.
• Detection time is the only practical information needed by veterinarians and horse industry that EHLSC can release
![Page 43: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/43.jpg)
43
What is a detection time•DT is the time at which the urinary (or plasma) concentrations of a drug, in all horses involved in a particular trial conducted according to the EHSLC guidance rules, are observed to be lower than the ISL when controls are performed using routine screening methods.
ISL
time
DT
![Page 44: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/44.jpg)
44
![Page 45: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/45.jpg)
45
![Page 46: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/46.jpg)
46
Detection Time
• Detection time is not a parameter but a variable without statistical protection
– dose, route of administration, formulation, number of administrations etc.
![Page 47: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/47.jpg)
47
Why some DT are so long?
2/144.11
TSF
LnDT
Safety Factor
Half-life (h)
100
DT (days)
500
DT (days)
12 3.31 4.47
24 6.63 8.94
48 13.26 17.89
![Page 48: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/48.jpg)
48
From the Detection Timeto a Withdrawal period
![Page 49: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/49.jpg)
49
EHLSC decided to release Detection
times (DT) an not Withdrawal time (WT)
• DT: An information given by Authorities without statistical protection
• WT: A Vet recommendation based on his own risk analysis
![Page 50: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/50.jpg)
50
Main factors affecting a WT
Dosage regimen:
• Dose
• Dosage interval
• Route of administration
• Site of administration
• etc
Drug
• formulation
• Source
• vehicle
Horse:
• Breed
• Age
• Sex
• Health status
• Food
• Rest/activity
• Training/out of training
Definition and the selected experimental design to determine the WT:
• Number of horses
• Sampling time
• Urine pH
It is not the responsibility of EHLSC to guarantee a WP
![Page 51: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/51.jpg)
51
From a detection time to a withdrawal time
• To help the veterinarian select a WT from a published DT the question of a safety span was explored using Monte Carlo Simulations (MCSs) (Toutain 2010.)
![Page 52: 1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;](https://reader035.vdocuments.mx/reader035/viewer/2022062321/56649e4a5503460f94b3ee85/html5/thumbnails/52.jpg)
52
Conclusions
• To help FEI, I will suggest that FEI should:1. Express formally what are its values and amongst
them, what is the priority:– A level playing field vs. animal welfare
2. Follow the principles of the risk analysis to take its decision (ISL) in order to take into account competitive interests in an unbiased and transparent approach.
– Science and management are two different issues– Science can describe the world, but science cannot prescribe
what the world should be
3. Generate its own Detection Times or better, to initiate (participate) to international survey aiming to document factor of variability's of DT (population pharmacokinetics)